Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab
pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.